Immunopathogenesis of ocular toxoplasmosis and implications for treatment

References

• Gomez-Marin JE, de-la-Torre A Ocular disease due to Toxoplasma gondii. Toxoplasma gondii [Internet]. Elsevier; 2020 [cited 2023 Jan 24]. p. 229–291. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780128150412000050
   Google Scholar
• Rahmanian V, Rahmanian K, Jahromi A, et al. Seroprevalence of toxoplasma gondii infection: an umbrella review of updated systematic reviews and meta-analyses. J Family Med Prim Care [Internet]. 2020 [cited 2023 Feb 13];9:3848. 8. doi: 10.4103/jfmpc.jfmpc_753_20
   PubMedGoogle Scholar
• Dubey JP. Toxoplasmosis – a waterborne zoonosis. Vet Parasitol Internet. 2004;126(1–2):57–72. doi: 10.1016/j.vetpar.2004.09.005
   PubMed Web of Science ®Google Scholar
• Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans.Int J Parasitol Internet. 2000 [cited 2015 Aug 5];30(12–13):1217–1258. doi: 10.1016/S0020-7519(00)00124-7
   PubMed Web of Science ®Google Scholar
• Nsiangani Lusambo N, Kaimbo Wa Kaimbo D, Mumba Ngoyi D, et al. Clinical and serological characteristics of ocular toxoplasmosis in the democratic Republic of Congo. 2022. Internet [cited 2023 Jul 17]; doi: 10.1080/0927394820222140297
   Google Scholar
• Lusambo NN, Kaimbo Wa Kaimbo D, Mumba Ngoyi D. Risk factors for ocular toxoplasmosis among uveitis patients in Kinshasa, DR Congo.BMJ Open Ophthalmol Internet. 2023 [cited 2023 Jul 17];8(1):1198. doi: 10.1136/bmjophth-2022-001198
   Web of Science ®Google Scholar
• Gómez-Marín JE, Muñoz-Ortiz J, Mejía-Oquendo M, et al. High frequency of ocular toxoplasmosis in Quindío, Colombia and risk factors related to the infection. Heliyon Internet. 2021 [cited 2021 Apr 8];7(4):e06659. doi: 10.1016/j.heliyon.2021.e06659
   PubMed Web of Science ®Google Scholar
• Ferreira AIC, De Mattos CCB, Frederico FB, et al. Risk factors for ocular toxoplasmosis in Brazil. Epidemiol Infect [Internet]. 2014 [cited 2020 Feb 28];142(1):142–148. doi: 10.1017/S0950268813000526
   PubMed Web of Science ®Google Scholar
• Robert-Gangneux F, Dardé M-L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev Internet. 2012;25(2):264–296. doi: 10.1128/CMR.05013-11
   PubMed Web of Science ®Google Scholar
• Petersen E, Kijlstra A, Stanford M. Epidemiology of ocular toxoplasmosis. Ocul Immunol Inflamm. 2012;20(2):68–75. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/22409558%5Cnhttp://informahealthcare.com/doi/abs/10.3109/09273948.2012.661115
   PubMed Web of Science ®Google Scholar
• Milne GC, Webster JP, Walker M. Is the incidence of congenital toxoplasmosis declining? Trends Parasitol Internet. 2023 [cited 2023 Jan 25];39(1):26–37. doi: 10.1016/j.pt.2022.10.003
   PubMed Web of Science ®Google Scholar
• Mejia-Oquendo M, Marulanda-Ibarra E, Gomez-Marin JE. Evaluation of the impact of the first evidence-based guidelines for congenital toxoplasmosis in Armenia (Quindío) Colombia: an observational retrospective analysis. Lancet Reg Health - Am Internet. 2021 [cited 2023 Feb 24];1:100010. doi: 10.1016/j.lana.2021.100010
   PubMedGoogle Scholar
• Hou JH, Patel SS, Farooq AV, et al. Decline in ocular toxoplasmosis over 40 years at a tertiary referral practice in the United States. Ocul Immunol InflammInternet. 2018 [cited 2023 Jul 17];26:577–583. https://click.endnote.com/viewer?doi=10.1080%2F09273948.2016.1246665&token=WzEwNzI1NCwiMTAuMTA4MC8wOTI3Mzk0OC4yMDE2LjEyNDY2NjUiXQ.XM8ZuJkfFpbxDBf3-0YhGhz-aK8
   PubMed Web of Science ®Google Scholar
• Cifuentes-González C, Zapata-Bravo E, Sierra-Cote MC, et al. Colombian ocular infectious Epidemiology study (COIES): ocular toxoplasmosis incidence and sociodemographic Characterization, 2015-2019. Inter J Infect Dis. 2022;117:349–355. doi: 10.1016/j.ijid.2022.02.028
   PubMed Web of Science ®Google Scholar
• Semenza JC, Rocklöv J, Ebi KL. Climate change and cascading risks from infectious disease. Infect Dis Ther. 2022;11(4):1371–1390. doi: 10.1007/s40121-022-00647-3
   PubMed Web of Science ®Google Scholar
• Pozio E. How globalization and climate change could affect foodborne parasites. Exp Parasitol Internet. 2020 [cited 2022 Jul 13];208:107807. doi: 10.1016/j.exppara.2019.107807
   PubMed Web of Science ®Google Scholar
• Gomez-Marin JE, Pinto Y, Lora F, et al. Recipe ingredients for re emergent protozoa: climatic change, rain, zoonosis, mountain and food. Infectio Internet. 2022 [cited 2023 Jan 25];26:381–383. doi: 10.22354/24223794.1080
   Google Scholar
• FAO; WHO. Multicriteria-based ranking for risk management of food-born parasites [Internet]. First. WHO; FAO, Editor. Microbiological Risk Assessment Series No. 23. Rome. Rome: FAO/WHO; 2014 [cited 2015 Oct 2]. Available from: http://www.fao.org/3/a-i3649e.pdf
   Google Scholar
• Jones JL, Dubey JP. Foodborne toxoplasmosis.Clin Infect Dis Internet. 2012 [cited 2015 Sep 18];55(6):845–851. doi: 10.1093/cid/cis508
   PubMed Web of Science ®Google Scholar
• Foodborne Disease Burden Epidemiology Reference Group 2007-2015. WHO estimates of the global burden of foodborne diseases: foodborne diseases burden epidemiology reference group 2007-2015 [Internet]. 2015 [cited 2022 Jul 8]. Available from: https://www.who.int/publications/i/item/9789241565165
   Google Scholar
• Shapiro K, Bahia-Oliveira L, Dixon B, et al. Environmental transmission of Toxoplasma gondii: oocysts in water, soil and food. Food Waterborne Parasitol Internet. 2019;15:e00049. doi: 10.1016/j.fawpar.2019.e00049
   PubMedGoogle Scholar
• Nessim J, Luna-Ramirez JC, Moreno-Gómez GA, et al. Estimations of the number people with mental diseases associated with toxoplasmosis and identification of risk factors by continent. Psychiatry Res Internet. 2023 [cited 2023 Mar 9];115130:115130. doi: 10.1016/j.psychres.2023.115130
   Google Scholar
• Palanisamy M, Madhavan B, Balasundaram M, et al. Outbreak of ocular toxoplasmosis in Coimbatore, India. Indian J Ophthalmol Internet. 2006;54(2):129. doi: 10.4103/0301-4738.25839
   PubMedGoogle Scholar
• Bowie WR, King AS, Werker DH, et al. Outbreak of toxoplasmosis associated with municipal drinking water. The BC toxoplasma investigation team. Lancet Internet. 1997;350(9072):173–177. doi: 10.1016/S0140-6736(96)11105-3
   PubMedGoogle Scholar
• Dubey JP. Outbreaks of clinical toxoplasmosis in humans: five decades of personal experience, perspectives and lessons learned. Parasites Vectors Internet. 2021 [cited 2023 Jan 25];14(1): doi: 10.1186/s13071-021-04769-4
   Web of Science ®Google Scholar
• Vaudaux JD, Muccioli C, James ER, et al. Identification of an atypical strain of Toxoplasma gondii as the cause of a waterborne outbreak of toxoplasmosis in Santa Isabel do Ivai, Brazil. J Infect Dis. 2010;202(8):1226–1233.
   PubMed Web of Science ®Google Scholar
• Arantes TEFF, Silveira C, Holland GN, et al. Ocular involvement following Postnatally acquired Toxoplasma gondii infection in Southern Brazil: a 28-year experience. Am J Ophthalmol Internet. 2015 [cited 2015 Jul 1];159(6):1002–1012.e2. doi: 10.1016/j.ajo.2015.02.015
   PubMed Web of Science ®Google Scholar
• Frenkel JK. Pathophysiology of toxoplasmosis. Parasitol Today Internet. 1988;4(10):273–278. doi: 10.1016/0169-4758(88)90018-X
   PubMedGoogle Scholar
• Sharma P, Chitnis CE. Key molecular events during host cell invasion by apicomplexan pathogens. Curr Opin Microbiol. 2013;16(4):432–437. doi: 10.1016/j.mib.2013.07.004
   PubMed Web of Science ®Google Scholar
• Blader IJ, Coleman BI, Chen C-T, et al. Lytic Cycle of Toxoplasma gondii : 15 Years Later. Annu Rev Microbiol [Internet]. 2015 [cited 2020 Oct 14];69:463–485. 1 doi: 10.1146/annurev-micro-091014-104100
   PubMed Web of Science ®Google Scholar
• Skariah S, McIntyre MK, Mordue DG. Toxoplasma gondii: determinants of tachyzoite to bradyzoite conversion.Parasitol Res Internet. 2010 [cited 2023 Jul 23];107(2):253–260. doi: 10.1007/s00436-010-1899-6
   PubMed Web of Science ®Google Scholar
• Greigert V, Bittich-Fahmi F, Pfaff AW. Pathophysiology of ocular toxoplasmosis: facts and open questions. Taylan Ozkan A, editor. PLoS Negl Trop Dis [Internet] Available from. 2020 [cited 2021 Sep 1];14(12):e0008905. doi: 10.1371/journal.pntd.0008905
   PubMed Web of Science ®Google Scholar
• Daré LO, Bruand P-E, Gérard D, et al. Associations of mental disorders and neurotropic parasitic diseases: a meta-analysis in developing and emerging countries. BMC Public Health [Internet]. 2019 [cited 2020 Mar 29];19(1):1645. doi: 10.1186/s12889-019-7933-4
   PubMed Web of Science ®Google Scholar
• Petersen E, Ajzenberg D, Mandelbrot L, et al. Protozoan Diseases: Toxoplasmosis. International Encyclopedia Of Public Health [Internet]. Amsterdan: Elsevier; 2017 [cited 2019 May 26]. p. 114–132. Available from: https://www.sciencedirect.com/science/article/pii/B9780128036785003611
   Google Scholar
• Xiao J. Toxoplasma-induced behavioral changes: an aspecific consequence of neuroinflammation. Trends Parasitol Internet. 2020 [cited 2021 Jun 5];36(4):317–318. doi: 10.1016/j.pt.2020.01.005
   PubMed Web of Science ®Google Scholar
• Flegr J. Effects of Toxoplasma on human behavior. Schizophr Bull Internet. 2007;33(3):757–760. doi: 10.1093/schbul/sbl074
   PubMed Web of Science ®Google Scholar
• Milne G, Webster JP, Walker M. Toxoplasma gondii: an underestimated threat? Trends Parasitol Internet. 2020 [cited 2021 Jun 5];36(12):959–969. doi: 10.1016/j.pt.2020.08.005
   PubMed Web of Science ®Google Scholar
• Flegr J. How and why Toxoplasma makes us crazy. Trends Parasitol. 2013;29(4):156–163. Internet: https://linkinghub.elsevier.com/retrieve/pii/S1471492213000202
   PubMed Web of Science ®Google Scholar
• Delair E, Latkany P, Noble AG, et al. Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm Internet. 2011;19(2):91–102. doi: 10.3109/09273948.2011.564068
   PubMed Web of Science ®Google Scholar
• Butler NJ, Furtado JM, Winthrop KL, et al. Ocular toxoplasmosis II: clinical features, pathology and management. Clin Exp Ophthalmol. 2013;41(1):95–108.
   PubMed Web of Science ®Google Scholar
• Huang PK, Jianping C, Vasconcelos-Santos DV, et al. Ocular toxoplasmosis in tropical areas: analysis and outcome of 190 patients from a multicenter collaborative study.Ocul Immunol Inflamm [Internet]. 2017 [cited 2023 Jul 24];26(8):1289–1296. doi: 10.1080/0927394820171367407
   PubMed Web of Science ®Google Scholar
• Bosch-Driessen LEHH, Berendschot TTJMJM, Ongkosuwito JV, et al. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmol. 2002;109(5):869–878.
   PubMed Web of Science ®Google Scholar
• de-la-Torre A, López-Castillo CA, Gómez-Marín JE. Incidence and clinical characteristics in a Colombian cohort of ocular toxoplasmosis. Eye Internet. 2009 [cited 2015 Jan 22];23(5):1090–1093. doi: 10.1038/eye.2008.219
   PubMed Web of Science ®Google Scholar
• Glasner PD, Silveira C, Kruszon-Moran D, et al. An unusually high prevalence of ocular toxoplasmosis in Southern Brazil. Am J Ophthalmol [Internet]. 1992 [cited 2023 Jul 23];114(2):136–144. doi: 10.1016/S0002-9394(14)73976-5
   PubMed Web of Science ®Google Scholar
• de-la-Torre A, González G, Díaz-Ramirez J, et al. Screening by Ophthalmoscopy for Toxoplasma Retinochoroiditis in Colombia. Am J Ophthalmol Internet. 2007 [cited 2015 Jan 22];143(2):354–356. doi: 10.1016/j.ajo.2006.09.048
   PubMed Web of Science ®Google Scholar
• Commodaro AG, Chiasson M, Sundar N, et al. Elevated toxoplasma gondii infection rates for retinas from eye banks, Southern Brazil. Emerg Infect Dis [Internet]. 2016 [cited 2023 Jul 23];22:691–693. 4. doi: 10.3201/eid2204.141819
   PubMed Web of Science ®Google Scholar
• Burnett AJ, Shortt SG, Isaac-Renton J, et al. Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. Ophthalmol. 1998;105(6):1032–1037.
   PubMed Web of Science ®Google Scholar
• de-la-Torre A, Valdés-Camacho J, de Mesa CL, et al. Coinfections and differential diagnosis in immunocompetent patients with uveitis of infectious origin. BMC Infect Dis Internet. 2019;19(1):91. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3613-8
   PubMed Web of Science ®Google Scholar
• Silveira C, Muccioli C, Holland GN, et al. Ocular involvement following an epidemic of Toxoplasma gondii infection in Santa Isabel do ivaí, Brazil. Am J Ophthalmol Internet. 2015 [cited 2015 Jul 18];159(6):1013–1021.e3. doi: 10.1016/j.ajo.2015.02.017
   PubMed Web of Science ®Google Scholar
• de-la-Torre A, Gómez-Marín J. Disease of the Year 2019: ocular toxoplasmosis in HIV-infected patients. Ocul Immunol Inflamm. 2020;28(7):1031–1039. Internet: https://www.tandfonline.com/doi/full/10.1080/09273948.2020.1735450
   PubMed Web of Science ®Google Scholar
• Garweg JG, Candolfi E. Immunopathology in ocular toxoplasmosis: facts and clues. Mem Inst Oswaldo Cruz Internet. 2009;104(2):211–220. doi: 10.1590/S0074-02762009000200014
   PubMed Web of Science ®Google Scholar
• Rougier S, Montoya JG, Peyron F. Lifelong persistence of Toxoplasma cysts: a questionable dogma? Trends Parasitol Internet. 2016 [cited 2016 Dec 25]; Available from;33(2):93–101. doi: 10.1016/j.pt.2016.10.007
   PubMed Web of Science ®Google Scholar
• Holland GN. Ocular toxoplasmosis: the influence of patient age. Mem Inst Oswaldo Cruz Internet. 2009;104(2):351–357. doi: 10.1590/S0074-02762009000200031
   PubMed Web of Science ®Google Scholar
• Papadia M, Aldigeri R, Herbort CP. The role of serology in active ocular toxoplasmosis.Int Ophthalmol Internet. 2011 [cited 2023 Jul 26];31(6):461–465. doi: 10.1007/s10792-011-9507-z
   PubMedGoogle Scholar
• Gómez-Marín JE, Montoya-de-Londoño MT, Castaño-Osorio JC, et al. Frequency of specific anti-Toxoplasma gondii IgM, IgA and IgE in Colombian patients with acute and chronic ocular toxoplasmosis. Mem Inst Oswaldo Cruz [Internet]. 2000 [cited 2015 Jan 22];95(1):89–94. doi: 10.1590/S0074-02762000000100014
   PubMed Web of Science ®Google Scholar
• Ongkosuwito JV, Bosch-Driessen EH, Kijlstra A, et al. Serologic evaluation of patients with primary and recurrent ocular toxoplasmosis for evidence of recent infection. Am J Ophthalmol Internet. 1999;128(4):407–412. doi: 10.1016/S0002-9394(99)00266-4
   PubMed Web of Science ®Google Scholar
• Bonfioli AA, Orefice F. Toxoplasmosis. Semin Ophthalmol. 2005;20(3):129–141. doi: 10.1080/08820530500231961
   PubMedGoogle Scholar
• Wilder HC. TOXOPLASMA CHORIORETINITIS in ADULTS. AMA Arch Ophthalmol.Arch Ophtalmol Internet. 1952 [cited 2023 Jul 23];48(2):127–136. doi: 10.1001/archopht.1952.00920010132001
   PubMedGoogle Scholar
• Gallagher MJ, Yilmaz T, Cervantes-Castañeda RA, et al. The characteristic features of optical coherence tomography in posterior uveitis. Br J Ophthalmol [Internet]. 2007 [cited 2023 Jul 24];91(12):1680–1685. doi: 10.1136/bjo.2007.124099
   PubMed Web of Science ®Google Scholar
• Sofia O, Wahyudi INSA, Susianti H, et al. Optical coherence tomography angiography findings in ocular toxoplasmosis with Multiple recurrences. Int Med Case Rep J Internet. 2023 [cited 2023 Feb 5];16:35–43. doi: 10.2147/IMCRJ.S395600
   PubMed Web of Science ®Google Scholar
• Oréfice JL, Costa RA, Campos W, et al. Third-generation optical coherence tomography findings in punctate retinal toxoplasmosis. Am J Ophthalmol. 2006;142(3):503–505.e2.
   PubMed Web of Science ®Google Scholar
• Oréfice JL, Costa RA, Scott IU, et al. Spectral optical coherence tomography findings in patients with ocular toxoplasmosis and active satellite lesions (MINAS report 1). Acta Ophthalmol [Internet]. 2013 [cited 2023 Jul 24];91(1):e41–e47. doi: 10.1111/j.1755-3768.2012.02531.x
   PubMed Web of Science ®Google Scholar
• Diniz B, Regatieri, Andrade R, et al. Evaluation of spectral domain and time domain optical coherence tomography findings in toxoplasmic retinochoroiditis. Clin Ophthalmol Internet. 2011;5:645. http://www.dovepress.com/evaluation-of-spectral-domain-and-time-domain-optical-coherence-tomogr-peer-reviewed-article-OPTH
   PubMedGoogle Scholar
• Smith JR, Ashander LM, Arruda SL, et al. Pathogenesis of ocular toxoplasmosis. Prog Retin Eye Res [Internet]. 2021 [cited 2023 Jul 26];81:100882. doi: 10.1016/j.preteyeres.2020.100882
   PubMed Web of Science ®Google Scholar
• Carme B, Bissuel F, Ajzenberg D, et al. Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana. J Clin Microbiol Internet. 2002;40(11):4037–4044. doi: 10.1128/JCM.40.11.4037-4044.2002
   PubMed Web of Science ®Google Scholar
• Matet A, Paris L, Fardeau C, et al. Clinical and biological factors associated with recurrences of severe toxoplasmic retinochoroiditis confirmed by aqueous humor analysis. Am J Ophthalmol. 2019;199:82–93. doi: 10.1016/j.ajo.2018.11.013
   PubMed Web of Science ®Google Scholar
• Cortés DA, Aguilar MC, Ríos HA, et al. Severe acute multi-systemic failure with bilateral ocular toxoplasmosis in immunocompetent patients from urban settings in Colombia: case reports. Am J Ophthalmol Case Rep Internet. 2020 [cited 2022 Jul 18];18:100661. doi: 10.1016/j.ajoc.2020.100661
   PubMedGoogle Scholar
• de-la-Torre A, Sauer A, Pfaff AW, et al. Severe South American ocular toxoplasmosis is associated with decreased ifn-γ/Il-17a and increased Il-6/Il-13 intraocular levels. Jardim A, editor. PLoS Negl Trop Dis [Internet].2013 [cited 2015 Jan 22];7(11):e2541. https://dx.plos.org/10.1371/journal.pntd.0002541
   PubMed Web of Science ®Google Scholar
• Mantilla-Muriel LE, Hernández-de-Los-Ríos A, Rincón M, et al. Serotyping, host genes and cytokines response in human ocular toxoplasmosis. Microb Pathog Internet. 2020 [[cited 2020 Sep 9]];148:104465. doi: 10.1016/j.micpath.2020.104465
   PubMed Web of Science ®Google Scholar
• Su C, Khan A, Zhou P, et al. Globally diverse Toxoplasma gondii isolates comprise six major clades originating from a small number of distinct ancestral lineages. Proc Natl Acad Sci U S A Internet. 2012;109(15):5844–5849. doi: 10.1073/pnas.1203190109
   PubMed Web of Science ®Google Scholar
• Khan A, Ajzenberg D, Mercier A, et al. Geographic separation of domestic and wild strains of Toxoplasma gondii in French Guiana Correlates with a monomorphic version of Chromosome1a. PLoS Negl Trop Dis. 2014;8(9):e3182.
   PubMed Web of Science ®Google Scholar
• Shwab EK, Jiang T, Pena HFJ, et al. The ROP18 and ROP5 gene allele types are highly predictive of virulence in mice across globally distributed strains of Toxoplasma gondii. Int J Parasitol [Internet]. 2016 [cited 2018 Dec 26];46(2):141–146. doi: 10.1016/j.ijpara.2015.10.005
   PubMed Web of Science ®Google Scholar
• Behnke MS, Khan A, Lauron EJ, et al. Rhoptry proteins ROP5 and ROP18 are Major murine virulence factors in genetically divergent South American strains of Toxoplasma gondii. Malik HS, editor. PLoS Genet [Internet] Available from. 2015 [cited 2018 Dec 26];11(8):e1005434. doi: 10.1371/journal.pgen.1005434
   PubMed Web of Science ®Google Scholar
• Bertranpetit E, Jombart T, Paradis E, et al. Phylogeography of Toxoplasma gondii points to a South American origin. Infect Genet Evol Internet. 2017;48:150–155. doi: 10.1016/j.meegid.2016.12.020
   PubMed Web of Science ®Google Scholar
• Gazzinelli RT, Mendonça-Neto R, Lilue J, et al. Innate resistance against Toxoplasma gondii: an evolutionary tale of mice, cats, and men. Cell Host Microbe Cell Press. 2014;15(2):132–138.
   PubMed Web of Science ®Google Scholar
• Lehmann T, Marcet PL, Graham DH, et al. Globalization and the population structure of Toxoplasma gondii. Proc Natl Acad Sci U S A Internet. 2006;103(30):11423–11428. doi: 10.1073/pnas.0601438103
   PubMed Web of Science ®Google Scholar
• Wang J-L, Li T-T, Elsheikha HM, et al. Functional Characterization of Rhoptry Kinome in the virulent Toxoplasma gondii RH strain. Front Microbiol Internet. 2017;8:1–8. doi: 10.3389/fmicb.2017.00084
   PubMed Web of Science ®Google Scholar
• Chen L, Christian DA, Kochanowsky JA, et al. The Toxoplasma gondii virulence factor ROP16 acts in cis and trans, and suppresses T cell responses. J Exp Med. 2020 [[cited 2020 Oct 14]];217(3): Internet. doi: 10.1084/jem.20181757
   Web of Science ®Google Scholar
• Butcher BA, Fox BA, Rommereim LM, et al. Toxoplasma gondii rhoptry kinase ROP16 activates STAT3 and STAT6 resulting in cytokine inhibition and arginase-1-dependent growth control. Hunter CA, editor. PLoS Pathog [Internet] Available from. 2011 [cited 2020 Oct 14];7(9):e1002236. doi: 10.1371/journal.ppat.1002236
   PubMed Web of Science ®Google Scholar
• Saeij JPJ, Coller S, Boyle JP, et al. Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologue. Nature. 2007;445(7125):324–327.
   PubMed Web of Science ®Google Scholar
• Fentress SJ, Steinfeldt T, Howard JC, et al. The arginine-rich N-terminal domain of ROP18 is necessary for vacuole targeting and virulence of Toxoplasma gondii. Cell Microbiol. 2012;14(12):1921–1933.
   PubMed Web of Science ®Google Scholar
• Sánchez V, De-la-Torre A, Gómez-Marín JE. Characterization of ROP18 alleles in human toxoplasmosis.Parasitol Int Internet. 2014 [cited 2015 Jan 17];63(2):463–469. doi: 10.1016/j.parint.2013.10.012
   PubMed Web of Science ®Google Scholar
• Behnke MS, Khan A, Wootton JC, et al. Virulence differences in Toxoplasma mediated by amplification of a family of polymorphic pseudokinases. Proc Natl Acad Sci U S A [Internet]. 2011 [cited 2023 Jul 26];108(23):9631–9636. doi: 10.1073/pnas.1015338108
   PubMed Web of Science ®Google Scholar
• Bayram Delibaş S, Turgay N, Gürüz AY The role of cytokines in the immunopathogenesis of toxoplasmosis. Turkiye Klinikleri J Med Sci. 2009;29:1217–1221.
   Google Scholar
• de-la-Torre A, Pfaff AW, Grigg ME, et al. Ocular cytokinome is linked to clinical characteristics in ocular toxoplasmosis. Cytokine Internet. 2014;68(1):23–31. http://www.ncbi.nlm.nih.gov/pubmed/24787053
   PubMed Web of Science ®Google Scholar
• Cone RE, Pais R. Anterior Chamber-associated immune Deviation (ACAID): an acute response to ocular insult protects from Future immune-mediated damage? Internet. 2009 [cited 2023 Jul 25];1;OED.S2858. https://click.endnote.com/viewer?doi=10.4137%2Foed.s2858&token=WzEwNzI1NCwiMTAuNDEzNy9vZWQuczI4NTgiXQ.BMb28RbIx80X-cQ7TJdeDSmVCUE
   Google Scholar
• Acosta Davila JA, Hernandez De Los Rios A, Acosta JAD, et al. An overview of peripheral blood mononuclear cells as a model for immunological Research of Toxoplasma gondii and other apicomplexan parasites. Front Cell Infect Microbiol Internet. 2019 [cited 2019 May 15];9:24. doi: 10.3389/fcimb.2019.00024
   PubMed Web of Science ®Google Scholar
• Costantini S, Castello G, Colonna G. Human cytokinome: a new challenge for systems biology.Bioinformation Internet. 2010 [cited 2016 Nov 14];5(4):166–167. doi: 10.6026/97320630005166
   PubMedGoogle Scholar
• Frickel EM, Hunter CA. Lessons from toxoplasma: Host responses that mediate parasite control and the microbial effectors that subvert them. J Exp Med Internet. 2021 [cited 2022 Jan 23];218(11): doi: 10.1084/jem.20201314
   PubMed Web of Science ®Google Scholar
• Fisch D, Clough B, Frickel E-M. Human immunity to Toxoplasma gondii. Coers J, editor. PLoS Pathog [Internet]. 2019;15(12):e1008097. Available from: https://dx.plos.org/10.1371/journal.ppat.1008097
   PubMed Web of Science ®Google Scholar
• Ooi KGJ, Galatowicz G, Calder VL, et al. Cytokines and Chemokines in uveitis – is there a correlation with clinical phenotype? Clinical Medicine & Research Internet. 2006 [cited 2023 Jul 25];4(4):294–309. doi: 10.3121/cmr.4.4.294
   PubMedGoogle Scholar
• Maia MM, Meira-Strejevitch CS, Pereira-Chioccola VL, et al. Evaluation of gene expression levels for cytokines in ocular toxoplasmosis. Parasite Immunol Internet. 2017;39(10):e12462. doi: 10.1111/pim.12462
   Web of Science ®Google Scholar
• Thieme C, Schlickeiser S, Metzner S, et al. Immune Mediator profile in aqueous humor differs in patients with primary acquired ocular toxoplasmosis and recurrent acute ocular toxoplasmosis. Mediators Inflamm Internet. 2019 [[cited 2023 Jul 25]];2019:1–12. doi: 10.1155/2019/9356728
   Web of Science ®Google Scholar
• Sauer A, Rochet E, Lahmar I, et al. The local immune response to intraocular Toxoplasma re-challenge: less pathology and better parasite control through Treg/Th1/Th2 induction. Int J Parasitol Internet. 2013;43(9):721–728. doi: 10.1016/j.ijpara.2013.04.004
   PubMed Web of Science ®Google Scholar
• Sauer A, Villard O, Creuzot-Garcher C, et al. Intraocular levels of interleukin 17A (IL-17A) and IL-10 as respective determinant markers of toxoplasmosis and viral uveitis. Papasian CJ, editor. Clin Vaccin Immunol [Internet]. 2015 [cited 2017 Mar 5];22(1):72–78. doi: 10.1128/CVI.00423-14
   PubMed Web of Science ®Google Scholar
• Sauer A, Pfaff AW, Villard O, et al. Interleukin 17A as an effective target for anti-inflammatory and antiparasitic treatment of toxoplasmic uveitis. J Infect Dis. 2012;206(8):1319–1329.
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos D, Kalogeropoulos C, Sakkas H, et al. Pathophysiological aspects of ocular toxoplasmosis: host-parasite interactions. Ocul Immunol Inflamm [Internet]. 2022 [cited 2023 Jul 26];30(3):560–569. doi: 10.1080/09273948.2021.1922706
   PubMed Web of Science ®Google Scholar
• Naranjo-Galvis CA, de-la-Torre A, Mantilla-Muriel LE, et al. Genetic polymorphisms in cytokine genes in Colombian patients with ocular toxoplasmosis. Adams JH, editor. Infect Immun Internet. 2018;86(4): doi: 10.1128/IAI.00597-17
   PubMed Web of Science ®Google Scholar
• Cordeiro CA, Moreira PR, Costa GC, et al. Interleukin-1 gene polymorphisms and toxoplasmic retinochoroiditis. Mol VisInternet. 2008 [cited 2017 May 11];14:1845–1849. http://www.ncbi.nlm.nih.gov/pubmed/18941541
   PubMed Web of Science ®Google Scholar
• de Neves ES, Curi ALL, de Albuquerque MC, et al. Genetic polymorphism for IFNγ +874T/A in patients with acute toxoplasmosis. Rev Soc Bras Med Trop Internet. 2012 [cited 2017 May 11];45(6):757–760. doi: 10.1590/S0037-86822012000600020
   PubMed Web of Science ®Google Scholar
• de Albuquerque MC, Do Aleixo ALQ C, Benchimol EI, et al. The IFN-³+874T/A gene polymorphism is associated with retinochoroiditis toxoplasmosis susceptibility. Mem Inst Oswaldo Cruz Internet. 2009 [cited 2017 May 11];104(3):451–455. doi: 10.1590/S0074-02762009000300009
   PubMed Web of Science ®Google Scholar
• Cordeiro CA, Moreira PR, Andrade MS, et al. Interleukin-10 gene polymorphism (−1082G/A) is associated with Toxoplasmic Retinochoroiditis. Invest Ophthalmol Vis Sci Internet. 2008 [cited 2017 May 11];49(5):1979–1982. doi: 10.1167/iovs.07-1393
   PubMed Web of Science ®Google Scholar
• Torres-Morales E, Taborda L, Cardona N, et al. Th1 and Th2 immune response to P30 and ROP18 peptides in human toxoplasmosis. Med Microbiol Immunol [Internet]. 2014 [cited 2015 Jan 22];203(5):315–322. doi: 10.1007/s00430-014-0339-0
   PubMed Web of Science ®Google Scholar
• Maia MM, Meira-Strejevitch CS, Pereira-Chioccola VL, et al. Evaluation of gene expression levels for cytokines in ocular toxoplasmosis. Parasite Immunol Internet. 2017 [cited 2023 Jul 26];39(10):e12462. doi: 10.1111/pim.12462
   Web of Science ®Google Scholar
• Pfaff AW, de-la-Torre A, Rochet E, et al. New clinical and experimental insights into old world and neotropical ocular toxoplasmosis. Int J Parasitol [Internet]. 2014 [cited 2015 Jan 22];44(2):99–107. doi: 10.1016/j.ijpara.2013.09.007
   PubMed Web of Science ®Google Scholar
• Rudzinski M, Pardini L, Bernstein M, et al. Interferon-γ and il-10 release assay for patients with ocular toxoplasmosis. Am J Trop Med Hyg [Internet]. 2020 [cited 2023 Jul 26];103(6):2239–2243. doi: 10.4269/ajtmh.20-0124
   PubMed Web of Science ®Google Scholar
• Barbosa BF, Lopes-Maria JB, Gomes AO, et al. IL10, TGF Beta1, and IFN gamma modulate intracellular signaling pathways and cytokine production to control Toxoplasma gondii infection in BeWo trophoblast Cells1. Biol Reprod. 2015;92(3). doi: 10.1095/biolreprod.114.124115
   PubMed Web of Science ®Google Scholar
• Cai Y, Shen J. Modulation of host immune responses to Toxoplasma gondii by microRnas. Parasite Immunol Internet. 2017 [cited 2023 Jul 26];39(2):e12417. doi: 10.1111/pim.12417
   Web of Science ®Google Scholar
• Meira CS, Pereira-Chioccola VL, Vidal JE, et al. Cerebral and ocular toxoplasmosis related with IFN-γ, TNF-α, and IL-10 levels. Front Microbiol. 2014;5:105138. doi: 10.3389/fmicb.2014.00492
   Web of Science ®Google Scholar
• Mahmoudzadeh S, Nozad Charoudeh H, Marques CS, et al. The role of IL-12 in stimulating NK cells against Toxoplasma gondii infection: a mini-review. Parasitol Res. 2021;120(7):2303–2309.
   PubMed Web of Science ®Google Scholar
• Geiller B, Greigert V, Hillenbrand CA, et al. Type I and III interferons shape the retinal cytokine network and barrier function in an in vitro model of ocular toxoplasmosis. Front Immunol. 2023;14:1148037. doi: 10.3389/fimmu.2023.1148037
   PubMed Web of Science ®Google Scholar
• Roberts CW, Prasad S, Khaliq F, et al. Adaptive immunity and genetics of the host immune response. Toxoplasma Gondii [Internet]. Second Edi. Elsevier; 2014. p. 819–994. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780123964816000258
   Google Scholar
• Jamieson SE, Cordell H, Petersen E, et al. Host genetic and epigenetic factors in toxoplasmosis. Mem Inst Oswaldo Cruz. 2009;104(2):162–169.
   PubMed Web of Science ®Google Scholar
• Wujcicka W, Gaj Z, Wilczyński J, et al. Contribution of IL6 −174 G>C and IL1B +3954 C>T polymorphisms to congenital infection with Toxoplasma gondii. Eur J Clin Microbiol Infect Dis. 2015;34(11):2287–2294.
   PubMed Web of Science ®Google Scholar
• Cordeiro CA, MMoreira PR, Costa GC, et al. Interleukin-1 gene polymorphisms and toxoplasmic retinochoroiditis. Mol VisInternet. 2008 [cited 2023 Jul 29];14:1845–1849. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2568892/pdf/mv-v14-1845.pdf
   PubMed Web of Science ®Google Scholar
• Araujo WMR, Ayo CM, Previato M, et al. Role of interleukin 1β and interleukin 10 variants on ocular toxoplasmosis in Brazilian individuals. Front Ophthalmol Internet. 2023;3. https://www.frontiersin.org/articles/10.3389/fopht.2023.1183167/full
   Google Scholar
• Cordeiro CA, Moreira PR, Bessa TF, et al. Interleukin-6 gene polymorphism (−174 G/C) is associated with toxoplasmic retinochoroiditis. Acta Ophthalmol. 2013;91:e311–e314. doi: 10.1111/aos.12046
   PubMed Web of Science ®Google Scholar
• Abu EK, Boampong JN, Kyei S, et al. Associations between polymorphisms within interferon gamma and Tumor necrosis factor genes and Toxoplasma Retinochoroiditis in Ghanaian patients. Ocul Immunol Inflamm. 2017;25(5):683–689.
   Web of Science ®Google Scholar
• Cordeiro CA, Moreira PR, Costa GC, et al. TNF- gene polymorphism (-308G/A) and toxoplasmic retinochoroiditis. Br J Ophthalmol. 2008;92(7):986–988.
   PubMed Web of Science ®Google Scholar
• de Albuquerque MC, Do Aleixo AC, Benchimol EI, et al. The IFN-³+874T/A gene polymorphism is associated with retinochoroiditis toxoplasmosis susceptibility. Mem Inst Oswaldo Cruz. 2009;104(3):451–455.
   PubMed Web of Science ®Google Scholar
• Do Aleixo AC, Vasconcelos C, de Oliveira R, et al. Toxoplasmic retinochoroiditis: the influence of age, number of retinochoroidal lesions and genetic polymorphism for IFN-γ +874 T/A as risk factors for recurrence in a survival analysis. PLoS One. 2019;14(2):e0211627.
   PubMed Web of Science ®Google Scholar
• de S NE, Curi ALL, de AM, et al. Genetic polymorphism for IFNγ +874T/A in patients with acute toxoplasmosis. Rev Soc Bras Med Trop. 2012;45(6):757–760.
   PubMed Web of Science ®Google Scholar
• Peixe RG, Boechat MSB, Rangel ALP, et al. Single nucleotide polymorphisms in the interferon gamma gene are associated with distinct types of retinochoroidal scar lesions presumably caused by Toxoplasma gondii infection. Mem Inst Oswaldo Cruz. 2014;109(1):99–107.
   PubMed Web of Science ®Google Scholar
• de Faria Junior GM, Ayo CM, de Oliveira AP, et al. CCR5 chemokine receptor gene polymorphisms in ocular toxoplasmosis. Acta Trop. 2018;178:276–280. doi: 10.1016/j.actatropica.2017.12.012
   PubMed Web of Science ®Google Scholar
• Jamieson SE, Peixoto-Rangel AL, Hargrave AC, et al. Evidence for associations between the purinergic receptor P2X7 (P2RX7) and toxoplasmosis. Genes Immun. 2010;11(5):374–383.
   PubMed Web of Science ®Google Scholar
• Witola WH, Liu SR, Montpetit A, et al. ALOX12 in human toxoplasmosis. Infect Immun. 2014;82(7):2670–2679.
   PubMed Web of Science ®Google Scholar
• Peixoto-Rangel AL, Miller EN, Castellucci L, et al. Candidate gene analysis of ocular toxoplasmosis in Brazil: evidence for a role for toll-like receptor 9 (TLR9). Mem Inst Oswaldo Cruz. 2009;104(8):1187–1190.
   PubMed Web of Science ®Google Scholar
• Dutra MS, Bela SR, Peixoto-Rangel AL, et al. Association of a NOD2 gene polymorphism and T-Helper 17 cells with presumed ocular toxoplasmosis. J Infect Dis. 2013;207(1):152–163.
   PubMed Web of Science ®Google Scholar
• Witola WH, Mui E, Hargrave A, et al. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii -infected monocytic cells. Infect Immun. 2011;79(2):756–766.
   PubMed Web of Science ®Google Scholar
• Ayo CM, da Camargo AS, Frederico FB, et al. MHC class I Chain-related gene a polymorphisms and linkage disequilibrium with HLA-B and HLA-C alleles in ocular toxoplasmosis. PLoS One. 2015;10(12):e0144534.
   PubMed Web of Science ®Google Scholar
• Ayo CM, Frederico FB, Siqueira RC, et al. Ocular toxoplasmosis: susceptibility in respect to the genes encoding the KIR receptors and their HLA class I ligands. Sci Rep. 2016;6(1):36632.
   PubMedGoogle Scholar
• de Perce-da-Silva DS, Joaquim TE, Do Aleixo AC, et al. Influence of killer immunoglobulin-like receptors genes on the recurrence rate of ocular toxoplasmosis in Brazil. Mem Inst Oswaldo Cruz Internet. 2023;118 [[cited 2023 Jul 29]]. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762023000101103&tlng=en
   PubMed Web of Science ®Google Scholar
• Felix JPF, Lira RPC, Zacchia RS, et al. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. Am J Ophthalmol Internet. 2014;157(4):762–766.e1. doi: 10.1016/j.ajo.2013.12.022
   PubMed Web of Science ®Google Scholar
• Fernandes Felix JP, Cavalcanti Lira RP, Cosimo AB, et al. Trimethoprim-sulfamethoxazole versus placebo in reducing the risk of toxoplasmic retinochoroiditis recurrences: a three-year follow-up. Am J Ophthalmol Internet. 2016 [[cited 2019 Apr 26]];170:176–182. doi: 10.1016/j.ajo.2016.08.003
   PubMed Web of Science ®Google Scholar
• Amim LHLV, Pacheco AG, Fonseca-Costa J, et al. Role of IFN-γ +874 T/A single nucleotide polymorphism in the tuberculosis outcome among Brazilians subjects. Mol Biol Rep [Internet]. 2008 [cited 2023 Jul 28];35(4):563–566. doi:10.1007/s11033-007-9123-1
   PubMed Web of Science ®Google Scholar
• Sica A, Dorman L, Viggiano V, et al. Interaction of NF-κB and NFAT with the interferon-γ promoter. J Biol Chem. 1997;272(48):30412–30420.
   PubMed Web of Science ®Google Scholar
• Hernández-de-Los-Ríos A, Murillo-Leon M, Mantilla-Muriel LELE, et al. Influence of two major Toxoplasma gondii virulence factors (ROP16 and ROP18) on the immune response of peripheral blood mononuclear cells to human toxoplasmosis infection. Front Cell Infect Microbiol Internet. 2019;9:413. doi: 10.3389/fcimb.2019.00413
   PubMed Web of Science ®Google Scholar
• El-Bendary M, Neamatallah M, Elalfy H, et al. Association of interferon gamma gene polymorphism and susceptibility to hepatitis C virus infection in Egyptian patients: A multicenter, family‐based study. JGH Open [Internet]. 2017 [cited 2023 Jul 28];1:140 4 10.1002/jgh3.12024
   PubMed Web of Science ®Google Scholar
• Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-α, transforming growth factor-β, interleukin-10, interleukin-6, interferon-γ, and outcome of hepatitis C virus infection. J Med Virol. 2003;71(2):212–218.
   PubMed Web of Science ®Google Scholar
• Silva JLA, Rezende-Oliveira K, da Silva MV, et al. IL-17-expressing CD4+ and CD8+ T lymphocytes in human toxoplasmosis. Mediators InflammInternet. 2014 [cited 2017 Mar 5];2014:573825. http://www.hindawi.com/journals/mi/2014/573825/
   PubMed Web of Science ®Google Scholar
• Fatoohi F, Cozon GJN, Wallon M, et al. Systemic T cell response to Toxoplasma gondii antigen in patients with ocular toxoplasmosis. Jpn J Ophthalmol Internet. 2006;50(2):103–110. doi: 10.1007/s10384-005-0295-8
   PubMed Web of Science ®Google Scholar
• Feron EJ, Klaren VN, Wierenga EA, et al. Characterization of Toxoplasma gondii-specific T cells recovered from vitreous fluid of patients with ocular toxoplasmosis. Invest Ophthalmol Vis SciInternet. 2001 [cited 2018 Oct 26];42:3228–3232. https://iovs.arvojournals.org/article.aspx?articleid=2123203
   PubMed Web of Science ®Google Scholar
• Guan H, Moretto M, Bzik DJ, et al. NK cells enhance dendritic cell response against parasite antigens via NKG2D pathway. J Immunol. 2007;179(1):590–596.
   PubMed Web of Science ®Google Scholar
• Hunter CA. How are NK cell responses regulated during infection? Exp Parasitol. 1996;84(3):444–448. doi: 10.1006/expr.1996.0133
   PubMed Web of Science ®Google Scholar
• Sturge CR, Yarovinsky F, Andrews-Polymenis HL. Complex immune cell interplay in the gamma interferon response during Toxoplasma gondii infection.Infect Immun Internet. 2014 [cited 2023 Jul 26];82(8):3090–3097. doi: 10.1128/IAI.01722-14
   PubMed Web of Science ®Google Scholar
• Frenkel JK, Jacobs L. Ocular toxoplasmosis; pathogenesis, diagnosis and treatment. AMA Arch Ophthalmol. AMA Archives Of Ophthalmol Internet. 1958 [cited 2018 Jul 5];59(2):260–279. doi: 10.1001/archopht.1958.00940030128013
   PubMedGoogle Scholar
• Wilder HC. Toxoplasma chorioretinitis in adults: a preliminary study of forty-one Cases diagnosed by microscopic examination.AMA Arch Ophthalmol [Internet]. 1952 [[cited 2018 Jul 4]];47(4):425. doi: 10.1001/archopht.1952.01700030435003
   PubMedGoogle Scholar
• Mochizuki M, Sugita S, Kamoi K. Immunological homeostasis of the eye. 2012 [cited 2023 Jul 26]. doi: 10.1016/j.preteyeres.2012.10.002
   Google Scholar
• García-López LL, Vargas-Montes M, Osorio-Méndez JF, et al. CD8+ T–cell exhaustion phenotype in human asymptomatic and ocular toxoplasmosis.Ocul Immunol Inflamm Internet. 2023 [cited 2023 Jul 11].1–10. doi: 10.1080/0927394820232217906
   PubMed Web of Science ®Google Scholar
• Cordeiro CA, Vieira ELM, Castro VM, et al. T cell immunoregulation in active ocular toxoplasmosis. Immunol Lett Internet. 2017 [[cited 2023 Jul 26]];184:84–91. doi: 10.1016/j.imlet.2017.02.009
   PubMed Web of Science ®Google Scholar
• Sauer A, Pfaff AW, Villard O, et al. Interleukin 17A as an effective target for anti-inflammatory and antiparasitic treatment of toxoplasmic uveitis. J Infect Dis Internet. 2012 [[cited 2023 Jul 26]];206:1319–1329. doi:10.1093/infdis/jis486
   PubMed Web of Science ®Google Scholar
• Kelly MN, Kolls JK, Happel K, et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun. 2005;73(1):617–621.
   PubMed Web of Science ®Google Scholar
• Gaddi PJ, Yap GS. Cytokine regulation of immunopathology in toxoplasmosis.Immunol Cell Biol Internet. 2007 [cited 2023 Jul 26];85(2):155–159. doi: 10.1038/sj.icb.7100038
   PubMed Web of Science ®Google Scholar
• Dutra MS, Bela SR, Peixoto-Rangel AL, et al. Association of a NOD2 gene polymorphism and Th17 lymphocytes with presumed ocular toxoplasmosis. J Infect Dis Internet. 2012;207(1):152–163. http://www.ncbi.nlm.nih.gov/pubmed/23100559
   PubMed Web of Science ®Google Scholar
• Ashander LM, Lie S, Ma Y, et al. Neutrophil activities in human ocular toxoplasmosis: an in vitro study with human cells. Invest Ophthalmol Vis Sci [Internet]. 2019 [cited 2023 Jul 26];60(14):4652–4660. doi: 10.1167/iovs.19-28306
   PubMed Web of Science ®Google Scholar
• de Araújo TE, dos Santos LI, Gomes AO, et al. Putative biomarkers for early diagnosis and prognosis of congenital ocular toxoplasmosis. Sci Rep Internet. 2020 [cited 2023 Jul 26];10(11):1–14. doi: 10.1038/s41598-020-73265-z
   PubMed Web of Science ®Google Scholar
• Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation.Nat Immunol Internet. 2003 [cited 2023 Jul 28];4(9):835–842. doi: 10.1038/ni969
   PubMed Web of Science ®Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–499. doi: 10.1038/ni.2035
   PubMed Web of Science ®Google Scholar
• Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature Med 12:10Internet. 2006 [cited 2021 Aug 31];12(10):1198–1202. doi: 10.1038/nm1482
   PubMed Web of Science ®Google Scholar
• de Oliveira BC, da Silva AA, de Andrade Cavalcante MK, et al. Central and effector memory human CD4+ and CD8+ T cells during Cutaneous leishmaniasis and after in vitro stimulation with leishmania (viannia) braziliensis epitopes. Vaccines (Basel) Internet. 2023 [[cited 2023 Jul 11]];11(1): doi: 10.3390/vaccines11010158
   Web of Science ®Google Scholar
• Cifuentes-González C, Rojas-Carabali W, Pérez ÁO, et al. Risk factors for recurrences and visual impairment in patients with ocular toxoplasmosis: a systematic review and meta-analysis. PLoS One [Internet]. 2023 [cited 2023 Jul 28];18. 4 e0283845. doi: 10.1371/journal.pone.0283845
   PubMed Web of Science ®Google Scholar
• De-la-Torre A, Rios-Cadavid ACC, Cardozo-García CMM, et al. Frequency and factors associated with recurrences of ocular toxoplasmosis in a referral centre in Colombia. Br J Ophthalmol Internet. 2009;93(8):1001–1004. doi: 10.1136/bjo.2008.155861
   PubMed Web of Science ®Google Scholar
• Lin H-Y, Lee W-J. The role of corticosteroids in treating acute ocular toxoplasmosis in an immunocompetent patient: a case report. Front Med Internet. 2022;9. doi: 10.3389/fmed.2022.843050
   Web of Science ®Google Scholar
• Oray M, Ozdal PC, Cebeci Z, et al. Fulminant ocular toxoplasmosis: the hazards of corticosteroid monotherapy. Ocul Immunol Inflamm. 2016;24(6):637–646.
   PubMed Web of Science ®Google Scholar
• Garweg JG, Scherrer J, Wallon M, et al. Reactivation of ocular toxoplasmosis during pregnancy. BJOG [Internet]. 2005 [cited 2023 Jul 28];112(2):241–242. doi: 10.1111/j.1471-0528.2004.00302.x
   PubMed Web of Science ®Google Scholar
• Inchauspe S, Palacio A, Arriazu G, et al. Association between ocular Trauma and activation of ocular toxoplasmosis. Ocul Immunol Inflamm Internet. 2023 [cited 2023 Jul 28]; 1–5. https://click.endnote.com/viewer?doi=10.1080%2F09273948.2023.2203215&token=WzEwNzI1NCwiMTAuMTA4MC8wOTI3Mzk0OC4yMDIzLjIyMDMyMTUiXQ.q0vjbL8ahzWFPviXMj69q1rIV6Q
   PubMed Web of Science ®Google Scholar
• Lee KA, Flores RR, Jang IH, et al. Immune Senescence, Immunosenescence and Aging. Frontiers In Aging Internet. 2022 [cited 2023 Jul 28]; 3. doi: 10.3389/fragi.2022.900028
   Google Scholar
• Velasco-Velásquez S, Celis-Giraldo D, Botero Hincapié A, et al. Clinical, socio-economic and environmental factors related with recurrences in ocular toxoplasmosis in Quindío, Colombia. Ophthalmic Epidemiol Internet. 2020;28(3):258–264. https://www.tandfonline.com/doi/full/10.1080/09286586.2020.1839509
   PubMed Web of Science ®Google Scholar
• Jensen KDC, Camejo A, Melo MB, et al. Toxoplasma gondii superinfection and virulence during secondary infection correlate with the exact ROP5/ROP18 allelic combination. Weiss LM, editor. MBio [Internet]. 2015;6(2): doi: 10.1128/mBio.02280-14
   Web of Science ®Google Scholar
• Holland GN, Crespi CM, ten Dam-van Loon N, et al. Analysis of recurrence patterns associated with Toxoplasmic Retinochoroiditis. Am J Ophthalmol Internet. 2008;145(6):1007–1013.e1. doi: 10.1016/j.ajo.2008.01.023
   PubMed Web of Science ®Google Scholar
• Reich M, Ruppenstein M, Becker MD, et al. Time patterns of recurrences and factors predisposing for a higher risk of recurrence of ocular toxoplasmosis. Retina [Internet]. 2015 [cited 2023 Sep 24];35(4):809–819. doi: 10.1097/IAE.0000000000000361
   PubMed Web of Science ®Google Scholar
• Garweg JG, Pleyer U. Treatment strategy in human ocular toxoplasmosis: why antibiotics have failed. J Clin Med Internet. 2021 [[cited 2023 Sep 24]];10(5):1–20. doi: 10.3390/jcm10051090
   Web of Science ®Google Scholar
• Fentress SJ, Behnke MS, Dunay IR, et al. Phosphorylation of immunity-related GTPases by a Toxoplasma gondii-secreted kinase promotes macrophage survival and virulence. Cell Host Microbe [Internet]. 2010 [cited 2020 Oct 14];8(6):484–495. doi: 10.1016/j.chom.2010.11.005
   PubMed Web of Science ®Google Scholar
• BLADER IJ, SAEIJ JP. Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence. APMIS Internet. 2009;117(5–6):458–476. doi: 10.1111/j.1600-0463.2009.02453.x
   PubMed Web of Science ®Google Scholar
• Reich M, Becker MD, Mackensen F. Influence of drug therapy on the risk of recurrence of ocular toxoplasmosis. Br J Ophthalmol bjophthalmol-2015. 2015;100(2):195–199. doi: 10.1136/bjophthalmol-2015-306650
   PubMed Web of Science ®Google Scholar
• Gómez Marín JE. Possibilities for immunomodulation in congenital toxoplasmosis. J Infect Dis Internet. 2016 [cited 2016 Sep 13];214(4):656.1–656. doi: 10.1093/infdis/jiw210
   Web of Science ®Google Scholar
• Gómez Marín JE, El Bissati K. Editorial: Innovative Therapeutic and Immunomodulatory Strategies for Protozoan Infections. Front Cell Infect Microbiol Internet. 2019;9. doi: 10.3389/fcimb.2019.00293
   Web of Science ®Google Scholar
• Streilein JW. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation.Journal Of Leukocyte Biology Internet. 2003 [cited 2018 Oct 26];74(2):179–185. doi: 10.1189/jlb.1102574
   PubMed Web of Science ®Google Scholar
• Hu Z, Wu D, Lu J, et al. Inflammasome activation dampens type I IFN signaling to strengthen anti-Toxoplasma immunity. MBio. 2022 [[cited 2023 Jul 27]];13(6): Internet. doi: 10.1128/mbio.02361-22
   Web of Science ®Google Scholar
• Bretscher PA. On the mechanism determining the Th1/Th2 phenotype of an immune response, and its pertinence to strategies for the prevention, and treatment, of certain infectious diseases.Scand J Immunol Internet. 2014 [cited 2023 May 27];79(6):361–376. doi: 10.1111/sji.12175
   PubMed Web of Science ®Google Scholar
• McBride D, Kerr M, Dorn N, et al. Triggers, timescales, and treatments for cytokine-mediated tissue damage. EMJ Innovations Internet. 2020 [[cited 2023 Jul 27]]. https://click.endnote.com/viewer?doi=10.33590%2Femjinnov%2F20-00203&token=WzEwNzI1NCwiMTAuMzM1OTAvZW1qaW5ub3YvMjAtMDAyMDMiXQ.zIek2f43CMQ0WpRUMnWDoDoGHGc
   Google Scholar
• Mease PJ, Van Der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebocontrolled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum DisInternet. 2017 [cited 2023 Jul 27];76:79–87. https://click.endnote.com/viewer?doi=10.1136%2Fannrheumdis-2016-209709&token=WzEwNzI1NCwiMTAuMTEzNi9hbm5yaGV1bWRpcy0yMDE2LTIwOTcwOSJd.KrsXr2mzaaCvvXXLShfGu79Cchw
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med [Internet]. 2015 [cited 2023 Jul 27];373:1318–1328. 14 10.1056/NEJMoa1503824
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med [Internet]. 2015 [cited 2023 Jul 27];373(26):2534–2548. doi: 10.1056/NEJMoa1505066
   PubMed Web of Science ®Google Scholar
• Pepple KL, Lin P. Targeting interleukin-23 in the treatment of noninfectious uveitis.Ophthalmol Internet. 2018 [cited 2023 Jul 27];125(12):1977. doi: 10.1016/j.ophtha.2018.05.014
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatology [Internet]. 2018 [cited 2023 Jul 27];57:856–864. doi: 10.1093/rheumatology/kex480. 5
   PubMed Web of Science ®Google Scholar
• Syambani Ulhaq Z, Vita Soraya G, Retno Wulandari L. The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis. Sci Rep. 2020 [cited 2023 Jul 27];10(1). doi: 10.1038/s41598-020-74203-9
   Web of Science ®Google Scholar
• Yang JY, Goldberg D, Sobrin L. Interleukin-6 and Macular Edema: a review of Outcomes with inhibition. Int J Mol Sci 2023, Vol 24, Page 4676Internet. 2023 [cited 2023 Jul 27];24(5):4676. doi: 10.3390/ijms24054676
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Hussain RM, Taraborelli D, et al. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes. Ophthalmol Retina. 2022;6(9):796–806.
   PubMedGoogle Scholar